Changes in Beneficial Ownership · 4
Braveheart Bio, Inc.
BRVENASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-08112026_090855.xml
Filing details
- Report period
- 2026-08-07
- Issuer
- Braveheart Bio, Inc.
- Issuer CIK
- 0002131524
- Trading symbol
- BRVE
Reporting owner 1
- Name
- AH Bio Fund IV, L.P.
- Reporting owner CIK
- 0001889476
- Relationship
- 10% owner
- Address
- C/O ANDREESSEN HOROWITZ, 2865 SAND HILL ROAD, SUITE 101, MENLO PARK, CA, 94025
Reporting owner 2
- Name
- AH Equity Partners Bio IV, L.L.C.
- Reporting owner CIK
- 0001889898
- Relationship
- 10% owner
- Address
- C/O ANDREESSEN HOROWITZ, 2865 SAND HILL ROAD, SUITE 101, MENLO PARK, CA, 94025
Reporting owner 3
- Name
- Andreessen Marc L
- Reporting owner CIK
- 0001160077
- Relationship
- 10% owner
- Address
- C/O ANDREESSEN HOROWITZ, 2865 SAND HILL ROAD, SUITE 101, MENLO PARK, CA, 94025
Reporting owner 4
- Name
- HOROWITZ BENJAMIN A
- Reporting owner CIK
- 0001166586
- Relationship
- 10% owner
- Address
- C/O ANDREESSEN HOROWITZ, 2865 SAND HILL ROAD, SUITE 101, MENLO PARK, CA, 94025
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-07 | C · Form 4 | 9,132,420 | A | [F1] | 9,132,420 | I | By AH Bio Fund IV, L.P.[F2][F3] |
| Common Stock | 2026-08-07 | P · Form 4 | 1,100,000 | A | 18 | 10,232,420 | I | By AH Bio Fund IV, L.P.[F2][F3] |
Table key
- C · Form 4
- Derivative conversion
- A
- Acquired
- I
- Indirect
- P · Form 4
- Purchase on the market or privately
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred Stock | [F1] | 2026-08-07 | C · Form 4 | 40,000,000 | D | 0 | [F1] | [F1] | Common Stock | 9,132,420 | 0 | I | By AH Bio Fund IV, L.P.[F2][F3] |
Table key
- C · Form 4
- Derivative conversion
- D
- Disposed
- I
- Indirect
Footnotes
- F1
- Series A Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 4.38-for-1 basis. The Series A Preferred Stock had no expiration date.↩ 1↩ 2↩ 3↩ 4
- F2
- The reported securities are held by AH Bio Fund IV, L.P. ("AH Bio Fund IV"), for itself and as nominee for AH Bio Fund IV-B, L.P., AH 2022 Annual Fund, L.P., AH 2022 Annual Fund-B, L.P., AH 2022 Annual Fund-QC, L.P. and CLF Partners III, LP. AH Equity Partners Bio IV, L.L.C. ("AH EP Bio IV") is the general partner of AH Bio Fund IV and has sole voting and dispositive power with regard to the securities held by AH Bio Fund IV for itself and as nominee. The managing members of AH EP Bio IV are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund IV for itself and as nominee.↩ 1↩ 2↩ 3
- F3
- (Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH Bio Fund IV for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.↩ 1↩ 2↩ 3
Signature 1
- Signed
- AH Bio Fund IV, L.P., By AH Equity Partners Bio IV, L.L.C., Its General Partner, By /s/ Phil Hathaway, Chief Operating Officer
- Date
- 2026-08-11
Signature 2
- Signed
- AH Equity Partners Bio IV, L.L.C., By /s/ Phil Hathaway, Chief Operating Officer
- Date
- 2026-08-11
Signature 3
- Signed
- /s/ Phil Hathaway, Attorney-in-Fact for Marc L. Andreessen
- Date
- 2026-08-11
Signature 4
- Signed
- /s/ Phil Hathaway, Attorney-in-Fact for Benjamin Horowitz
- Date
- 2026-08-11
Company context
We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity. BHB-1893 was initially discovered and developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui”) in China. We in-licensed BHB-1893 pursuant to an exclusive license agreement with Hengrui (the “Exclusive License Agreement”), and as such, all clinical trials of BHB-1893 completed to date were designed, sponsored, and conducted by Hengrui, primarily in China, with one Phase 1 trial conducted in Australia. We were not involved in the design, conduct, or oversight of these trials.